Controversies surrounding androgen deprivation for prostate cancer.

@article{Patterson2002ControversiesSA,
  title={Controversies surrounding androgen deprivation for prostate cancer.},
  author={Stephen G Patterson and Lodovico Balducci and Julio M. Pow-Sang},
  journal={Cancer control : journal of the Moffitt Cancer Center},
  year={2002},
  volume={9 4},
  pages={
          315-25
        }
}
BACKGROUND Management of metastatic prostate cancer continues to evolve. The widespread use of the prostate-specific antigen (PSA) assay has led to earlier diagnosis and earlier detection of recurrent disease. Debates continue regarding the proper use and timing of endocrine therapy with orchiectomy, estrogen agonists, luteinizing hormone-releasing hormone (LHRH) analogs, LHRH antagonists, and androgen antagonists. METHODS The authors reviewed the significant published materials of the last… Expand
Endocrine approaches in the therapy of prostate carcinoma.
TLDR
Diethylstilbestrol therapy was associated with cardiovascular side-effects; GnRH agonists were able to create a castration level, but again considerable side- effects were described. Expand
Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients
TLDR
Hormonal replacement in patients that underwent castration seems to be feasible in improving intense symptoms associated to androgen deprivation, but the short follow-up and the small number of patients cannot allow for definitive conclusions and should be studied further. Expand
Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
TLDR
Patients with the most advanced prostate cancer and poorest prognosis do not show adequate biochemical prostate specific antigen response to androgen deprivation therapy but should be assessed for eligibility to receive nonendocrine treatment. Expand
Andropause: symptom management for prostate cancer patients treated with hormonal ablation.
TLDR
The current literature on the symptoms, signs, and possible therapies available to men who cannot take replacement testosterone, including the andropause syndrome, are reviewed. Expand
Androgenic impact on prostate cancer risk
TLDR
The aims of this thesis were to investigate if T concentrations or the combination of genetic variants in the AR could influence the risk of being diagnosed with PCa and if AR-variants could affect therisk of having PSA above clinical thresholds on the suspicion of PCa in men without PCa. Expand
PLEIOTROPIC EFFECTS OF XENOESTROGEN ACTION IN PROSTATE CANCER
TLDR
It is proposed that BPA activates specific nuclear receptors in advanced prostate cancers, thus inducing inappropriate CaP cell proliferation and facilitating the development of hormone-refractory prostate tumors, and supporting the notion that non-steroidal environmental compounds can alter the function of nuclear receptor complexes. Expand
Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance.
TLDR
Irrespective of patients' age, TNM, stage of illness, or histological background, the majority of prostate cancer patients in Japan are receiving hormone therapy, and it is necessary to evaluate whether this trend is merely a continuation of past experience of Japanese urologists or if there is a difference in the profile of effect and side-effect in the case of Japanese patients compared to therapy given in Westerners. Expand
Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy
TLDR
It is concluded that men treated with androgen deprivation therapy are at risk for bone loss and should have BMD measured at the time of initiation of androgens deprivation therapy and periodically. Expand
Deciphering the role of beta-catenin in prostate cancer
TLDR
In vivo, gain-offunction (stable, inducible PTEN PrCa cells) and loss-of-function (PTEN -/mouse model) analysis support that PTEN serves to regulate nuclear localization of p-catenin, indicating a dynamic and functional role for P- catenin in PrCa systems. Expand
Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
Background. Loss of bone density with androgen deprivation therapy for prostate cancer is well recognized. We assessed the effects of quarterly infusion of zoledronic acid on bone mineral densityExpand
...
1
2
...

References

SHOWING 1-10 OF 135 REFERENCES
Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer
TLDR
It is established that DES is equivalent to orchiectomy as a comparator for treatments of advanced prostate cancer and the findings on four questions are summarized. Expand
Intermittent androgen suppression in the management of prostate cancer.
TLDR
Intermittent androgen suppression can be used intermittently, and appears to be more appropriate for patients with local or biochemical failure, and Testosterone recovery is not universal in the off-treatment intervals. Expand
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
TLDR
The studies described herein outline an exciting era of research to define the optimal use of hormonal therapy in prostate cancer, with the discovery and development of GnRH antagonists providing an important advance for patients with prostate cancer. Expand
Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer.
TLDR
IAD appears to be a viable treatment option in select patients with localized prostate cancer, and with each consecutive cycle, the amount of time the patient was not receiving therapy decreased, despite achieving a low nadir PSA. Expand
Treatment of prostate cancer with gonadotropin-releasing hormone agonists.
TLDR
In order to inhibit the action of androgens of both testicular and adrenal origin, GnRH agonists have been administered in association with the pure antiandrogen Flutamide in patients having clinical stage D2 (bone metastases) prostate cancer. Expand
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
TLDR
The available information suggests that early androgen suppression for treatment of advanced prostate cancer reduces disease progression and complications due to progression and the lack of PSA testing for diagnostic and monitoring purposes. Expand
Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
TLDR
To accomplish this goal successfully, megestrol acetate was combined with DES or estradiol to suppress testicular function to castration levels and to block residual adrenal androgens at the cell level. Expand
Potential side‐effects of endocrine treatment of long duration in prostate cancer
  • R. Stege
  • Medicine
  • The Prostate. Supplement
  • 2000
TLDR
Since many prostate cancer patients are treated hormonally for many years, control of Hb levels and bone mineral density before and after initiation of treatment at regular intervals is highly recommended as a standard of care. Expand
A pilot study of intermittent androgen deprivation in advanced prostate cancer.
TLDR
The temporary cessation of hormone therapy early during the response in patients with metastatic carcinoma of prostate is associated with biochemical evidence of relatively early progression in most cases, but can be associated with significant periods off therapy and with a high chance of a second hormone response. Expand
Is the flare phenomenon clinically significant?
TLDR
There is a wide variation in the reported frequency of clinical flare responses from LHRH analogs during the initial treatment of patients with stage D2 disease, and the risk-to-benefit ratio would dictate routine use of antiandrogen therapy for the first month of L HRH analog treatment. Expand
...
1
2
3
4
5
...